Briefing
c-TRAK TN: ctDNA surveillance to trigger pembrolizumab in early triple-negative breast cancer
Phase 2 trial that uses serial ctDNA to detect residual disease after primary treatment for moderate- or high-risk early triple-negative breast cancer and to start pembrolizumab. ClinicalTrials.gov lists the status as unknown.
- Design: Phase 2 · Unknown